226 related articles for article (PubMed ID: 27476765)
1. Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: A United States cohort.
Mittal S; Kanwal F; Ying J; Chung R; Sada YH; Temple S; Davila JA; El-Serag HB
J Hepatol; 2016 Dec; 65(6):1148-1154. PubMed ID: 27476765
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA.
El-Serag HB; Kramer JR; Chen GJ; Duan Z; Richardson PA; Davila JA
Gut; 2011 Jul; 60(7):992-7. PubMed ID: 21257990
[TBL] [Abstract][Full Text] [Related]
3. Healthcare Costs Related to Treatment of Hepatocellular Carcinoma Among Veterans With Cirrhosis in the United States.
Kaplan DE; Chapko MK; Mehta R; Dai F; Skanderson M; Aytaman A; Baytarian M; D'Addeo K; Fox R; Hunt K; Pocha C; Valderrama A; Taddei TH;
Clin Gastroenterol Hepatol; 2018 Jan; 16(1):106-114.e5. PubMed ID: 28756056
[TBL] [Abstract][Full Text] [Related]
4. Natural History of Untreated Hepatocellular Carcinoma in a US Cohort and the Role of Cancer Surveillance.
Khalaf N; Ying J; Mittal S; Temple S; Kanwal F; Davila J; El-Serag HB
Clin Gastroenterol Hepatol; 2017 Feb; 15(2):273-281.e1. PubMed ID: 27521507
[TBL] [Abstract][Full Text] [Related]
5. Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease.
Sohn W; Kang D; Kang M; Guallar E; Cho J; Paik YH
Clin Mol Hepatol; 2022 Oct; 28(4):851-863. PubMed ID: 36263667
[TBL] [Abstract][Full Text] [Related]
6. Hepatocellular Carcinoma Surveillance Patterns and Outcomes in Patients With Cirrhosis.
Daher D; Seif El Dahan K; Cano A; Gonzales M; Ransom C; Jaurez E; Carranza O; Quirk L; Morgan T; Gopal P; Patel MS; Lieber S; Louissaint J; Cotter TG; VanWagner LB; Yang JD; Parikh ND; Yopp A; Rich NE; Singal AG
Clin Gastroenterol Hepatol; 2024 Feb; 22(2):295-304.e2. PubMed ID: 37573986
[TBL] [Abstract][Full Text] [Related]
7. Screening is associated with a lower risk of hepatocellular carcinoma-related mortality in patients with chronic hepatitis B.
Su F; Weiss NS; Beste LA; Moon AM; Jin GY; Green P; Berry K; Ioannou GN
J Hepatol; 2021 Apr; 74(4):850-859. PubMed ID: 33245934
[TBL] [Abstract][Full Text] [Related]
8. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis.
Singal AG; Zhang E; Narasimman M; Rich NE; Waljee AK; Hoshida Y; Yang JD; Reig M; Cabibbo G; Nahon P; Parikh ND; Marrero JA
J Hepatol; 2022 Jul; 77(1):128-139. PubMed ID: 35139400
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular Carcinoma Screening in a Contemporary Cohort of At-Risk Patients.
Daher D; Seif El Dahan K; Rich NE; Tayob N; Merrill V; Huang DQ; Yang JD; Kulkarni AV; Kanwal F; Marrero J; Parikh N; Singal AG
JAMA Netw Open; 2024 Apr; 7(4):e248755. PubMed ID: 38683607
[TBL] [Abstract][Full Text] [Related]
10. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States.
Davila JA; Henderson L; Kramer JR; Kanwal F; Richardson PA; Duan Z; El-Serag HB
Ann Intern Med; 2011 Jan; 154(2):85-93. PubMed ID: 21242365
[TBL] [Abstract][Full Text] [Related]
11. Validation of the Hepatocellular Carcinoma Early Detection Screening (HES) Algorithm in a Cohort of Veterans With Cirrhosis.
Tayob N; Christie I; Richardson P; Feng Z; White DL; Davila J; Corley DA; Kanwal F; El-Serag HB
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1886-1893.e5. PubMed ID: 30557738
[TBL] [Abstract][Full Text] [Related]
12. Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study.
Costentin CE; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Letouzé E; Imbeaud S; Zucman-Rossi J; Audureau E; Roudot-Thoraval F; Nahon P;
Gastroenterology; 2018 Aug; 155(2):431-442.e10. PubMed ID: 29729258
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular Carcinoma Diagnosis and Management in 2021: A National Veterans Affairs Quality Improvement Project.
Rogal SS; Taddei TH; Monto A; Yakovchenko V; Patton H; Merante M; Spoutz P; Chia L; Yudkevich J; Aytaman A; Rabiee A; John BV; Blechacz B; Cai CX; Gilles H; Shah AS; McCurdy H; Puri P; Jou J; Mazhar K; Dominitz JA; Anwar J; Morgan TR; Ioannou GN
Clin Gastroenterol Hepatol; 2024 Feb; 22(2):324-338. PubMed ID: 37460005
[TBL] [Abstract][Full Text] [Related]
14. Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System.
Tayob N; Richardson P; White DL; Yu X; Davila JA; Kanwal F; Feng Z; El-Serag HB
BMC Med Res Methodol; 2018 Jan; 18(1):1. PubMed ID: 29301497
[TBL] [Abstract][Full Text] [Related]
15. Validation of the Updated Hepatocellular Carcinoma Early Detection Screening Algorithm in a Community-Based Cohort of Patients With Cirrhosis of Multiple Etiologies.
Tayob N; Corley DA; Christie I; Almers L; Rahal AK; Richardson P; White DL; Davila J; Kanwal F; El-Serag HB
Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1443-1450.e6. PubMed ID: 32768590
[TBL] [Abstract][Full Text] [Related]
16. Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors.
Davila JA; Kramer JR; Duan Z; Richardson PA; Tyson GL; Sada YH; Kanwal F; El-Serag HB
Hepatology; 2013 May; 57(5):1858-68. PubMed ID: 23359313
[TBL] [Abstract][Full Text] [Related]
17. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.
Ioannou GN; Green P; Kerr KF; Berry K
J Hepatol; 2019 Sep; 71(3):523-533. PubMed ID: 31145929
[TBL] [Abstract][Full Text] [Related]
18. The alpha-fetoprotein serum is still reliable as a biomarker for the surveillance of hepatocellular carcinoma in Indonesia.
Jasirwan COM; Fahira A; Siregar L; Loho I
BMC Gastroenterol; 2020 Jul; 20(1):215. PubMed ID: 32646378
[TBL] [Abstract][Full Text] [Related]
19. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States.
Davila JA; Morgan RO; Richardson PA; Du XL; McGlynn KA; El-Serag HB
Hepatology; 2010 Jul; 52(1):132-41. PubMed ID: 20578139
[TBL] [Abstract][Full Text] [Related]
20. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.
Cabibbo G; Petta S; Barbara M; Attardo S; Bucci L; Farinati F; Giannini EG; Negrini G; Ciccarese F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Sacco R; Virdone R; Marra F; Mega A; Morisco F; Benvegnù L; Gasbarrini A; Svegliati-Baroni G; Foschi FG; Olivani A; Masotto A; Nardone G; Colecchia A; Persico M; Craxì A; Trevisani F; Cammà C;
J Hepatol; 2017 Jul; 67(1):65-71. PubMed ID: 28192185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
